7JMT

Crystal structure of schistosome BCL-2 bound to ABT-737


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.75 Å
  • R-Value Free: 0.255 
  • R-Value Work: 0.234 
  • R-Value Observed: 0.235 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

Optimization of Benzothiazole and Thiazole Hydrazones as Inhibitors of Schistosome BCL-2.

Nguyen, W.Lee, E.F.Evangelista, M.Lee, M.Harris, T.J.Colman, P.M.Smith, N.A.Williams, L.B.Jarman, K.E.Lowes, K.N.Haeberli, C.Keiser, J.Smith, B.J.Fairlie, W.D.Sleebs, B.E.

(2021) ACS Infect Dis 7: 1143-1163

  • DOI: https://doi.org/10.1021/acsinfecdis.0c00700
  • Primary Citation of Related Structures:  
    7JGV, 7JGW, 7JMT

  • PubMed Abstract: 

    Limited therapeutic options are available for the treatment of human schistosomiasis caused by the parasitic Schistosoma flatworm. The B cell lymphoma-2 (BCL-2)-regulated apoptotic cell death pathway in schistosomes was recently characterized and shown to share similarities with the intrinsic apoptosis pathway in humans. Here, we exploit structural differences in the human and schistosome BCL-2 (sBCL-2) pro-survival proteins toward a novel treatment strategy for schistosomiasis. The benzothiazole hydrazone scaffold previously employed to target human BCL-XL was repurposed as a starting point to target sBCL-2. We utilized X-ray structural data to inform optimization and then applied a scaffold-hop strategy to identify the 5-carboxamide thiazole hydrazone scaffold ( 43 ) with potent sBCL-2 activity (IC 50 30 nM). Human BCL-XL potency (IC 50 13 nM) was inadvertently preserved during the optimization process. The lead analogues from this study exhibit on-target activity in model fibroblast cell lines dependent on either sBCL-2 or human BCL-XL for survival. Further optimization of the thiazole hydrazone class is required to exhibit activity in schistosomes and enhance the potential of this strategy for treating schistosomiasis.


  • Organizational Affiliation

    The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
BCL-2 protein
A, B, C, D, E
A, B, C, D, E, F
210Schistosoma japonicumMutation(s): 0 
UniProt
Find proteins for A0A4Z2CSJ3 (Schistosoma japonicum)
Explore A0A4Z2CSJ3 
Go to UniProtKB:  A0A4Z2CSJ3
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupA0A4Z2CSJ3
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.75 Å
  • R-Value Free: 0.255 
  • R-Value Work: 0.234 
  • R-Value Observed: 0.235 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 100.021α = 90
b = 67.789β = 118.793
c = 100.907γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
Aimlessdata scaling
PHENIXphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Health and Medical Research Council (NHMRC, Australia)Australia1135421
National Health and Medical Research Council (NHMRC, Australia)Australia1143974
National Health and Medical Research Council (NHMRC, Australia)Australia1002227

Revision History  (Full details and data files)

  • Version 1.0: 2021-02-17
    Type: Initial release
  • Version 1.1: 2021-05-26
    Changes: Database references
  • Version 1.2: 2023-10-18
    Changes: Data collection, Database references, Refinement description